Basic Information
| LncRNA/CircRNA Name | HCP5 |
| Synonyms | NA |
| Region | GRCh38_6:31400702-31477506 |
| Ensemble | ENSG00000206337 |
| Refseq | NR_040662 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | follicular thyroid cancer |
| ICD-0-3 | NA |
| Methods | RNA-seq, qPCR, RNAi etc. |
| Sample | cell lines (FTC-133, FTC-238, Nthy-ori 3-1, HEK293T, HUVECs), FTC tissues |
| Expression Pattern | up-regulated |
| Function Description | Overexpression of HCP5 can promote the proliferation,migration,invasiveness and angiogenic ability of FTC cells.HCP5 and alpha-2,6-sialyltransferase 2 (ST6GAL2) were co-expressed in FTC.We hypothesised that ST6GAL2 may be regulated by HCP5, which would in turn mediate the activity of FTC cells.HCP5 functions as a competing endogenous RNA (ceRNA) and acts as a sponge for miR-22-3p, miR-186-5p and miR-216a-5p, which activates ST6GAL2. |
| Pubmed ID | 29515098 |
| Year | 2018 |
| Title | LncRNA HCP5 promotes follicular thyroid carcinoma progression via miRNAs sponge. |
External Links
| Links for HCP5 | GenBank HGNC NONCODE |
| Links for follicular thyroid cancer | OMIM COSMIC |